From Biomarker to Drug Target: Integrating ceRNA Networks and Pharmacogenomics to Reposition C5orf34 in Uterine Corpus Endometrial Cancer Therapy - PubMed
5 hours ago
- #ceRNA
- #UCEC
- #C5orf34
- C5orf34 expression is significantly higher in UCEC tissues compared to normal tissues.
- Elevated C5orf34 is linked to advanced clinical stage, older age, higher weight, and poorer survival outcomes (OS, PFS, DSS).
- C5orf34 is associated with pathways like cell cycle regulation, cytokine-cytokine receptor interaction, and immune-related processes.
- Negative correlation found between C5orf34 expression and immune cell infiltration, suggesting an immunosuppressive tumor microenvironment.
- C5orf34 expression is linked to resistance to drugs like AT-7519, Navitoclax, Tivozanib, Ruxolitinib, and Erlotinib.
- A ceRNA network (LNC01224/miR-455-5p/C5orf34) provides insights into C5orf34 regulatory mechanisms in UCEC.
- C5orf34 identified as a potential prognostic indicator and therapeutic target for UCEC.